LEADER 03790nam 2200841z- 450 001 9910404087203321 005 20231214133608.0 010 $a3-03928-041-4 035 $a(CKB)4100000011302266 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/53236 035 $a(EXLCZ)994100000011302266 100 $a20202102d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aMetabolomics in Neurodegenerative Disease 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (184 p.) 311 $a3-03928-040-6 330 $aThe range of human neurodegenerative diseases continues to pose significant unmet medical needs for societies around the world. The progressive and terminal nature of these conditions places a considerable personal burden on the individual affected but also on public health systems and health services. Tens of millions of people are indiscriminately affected by various dementias, which are rising at an alarming rate. There are no cures for many conditions, and it is clear that treatments applied as early as possible could greatly improve outcomes for patients. Therefore, new disease classification and diagnostic tools should be a key priority. Metabolomics represents a relatively new field of analytical science, which can be extremely useful in the early diagnosis of disease. The relatively unique feature of metabolites is that they sit at the intersection between the genetic background of an organism and its environment. Because many neurodegenerative diseases are not genetically inherited (instead having a range of known genetic risk factors and also a large number of unknown environmental triggers) the field of metabolomics offers great promise for the discovery of new, biologically, and clinically relevant biomarkers for neurodegenerative disorders. It is already bringing forward new knowledge in terms of the mechanisms of neurodegenerative disease. 610 $aglutamic acid 610 $adirect mass spectrometry 610 $aneurodegeneration 610 $a6-OHDA 610 $atargeted mass spectrometry 610 $amitochondrial dysfunction 610 $amyo-inositol 610 $ametabolomics 610 $abile acids 610 $asubacute mild traumatic brain injury 610 $aage-related macular degeneration 610 $ametabolic pathways 610 $aenergy metabolism 610 $amidbrain 610 $aAlzheimer's disease 610 $abiomarkers 610 $a1H NMR 610 $aParkinson's disease dementia 610 $aGC-MS 610 $apathogenesis 610 $atricarboxylic acid cycle 610 $amicro-dialysis 610 $a13C-labeled succinate 610 $ametabolism 610 $alipidomics 610 $adementia with Lewy bodies 610 $afatty acid 610 $aprodromal Parkinson's disease 610 $amalonate 610 $acerebral ischemia 610 $amass spectrometry 610 $aretinal pigment epithelium 610 $aexcitotoxicity 610 $aendothelin-1 610 $areperfusion 610 $aC. elegans 610 $aStreptomyces venezuelae 610 $a?-synuclein aggregates 610 $anatural product 610 $afatty acid metabolism 610 $aimaging mass spectrometry 610 $aLC-MS 610 $adrusen 610 $acerebral palsy 610 $aplasma 610 $aParkinson's disease 700 $aGreen$b Brian$4auth$0732791 906 $aBOOK 912 $a9910404087203321 996 $aMetabolomics in Neurodegenerative Disease$93032111 997 $aUNINA